Tolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced CLL and NHL

Drug Category: Array
Conference Category: Array
Lead Author: Nastoupil L, et al.
Published Date: 16/06/2017
Download Link: /wp-content/uploads/2019/03/Final%20U2%20Ibrutinib%20ICML%20Nastoupil%202017.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top